Back

The RNA Editome of Esophageal Squamous Cell Carcinoma Identifies an ADAR1-CDK13 Editing Feedback Loop Mediating cGAS-STING Activation in Early Tumorigenesis

Huang, L.; Yang, M.; Li, D.; Jiang, G.; Zhang, W.

2026-01-30 cancer biology
10.64898/2026.01.29.701210 bioRxiv
Show abstract

ObjectiveRNA adenosine-to-inosine (A-to-I) editing, catalyzed by adenosine deaminases acting on RNA (ADARs), is a pervasive post-transcriptional mechanism that expands transcriptomic and proteomic diversity. However, the global landscape of RNA A-to-I editing, as well as its functional and clinical significance in esophageal squamous cell carcinoma (ESCC), remains largely unexplored. This study aimed to systematically characterize the RNA editome of ESCC and elucidate its biological and clinical significance. MethodsWhole-transcriptome sequencing was performed on 121 primary ESCC tumors, with or without lymph node metastasis, together with matched normal tissues, to construct a high-resolution RNA editome. ADAR1-regulated RNA editing events were identified, and their functional consequences were investigated using integrated transcriptomic, phosphoproteomic, and RNA immunoprecipitation sequencing (RIP-seq) analyses. Associations between CDK13 editing, cGAS-STING-interferon-stimulated gene (ISG) signaling, and patient survival were further evaluated. ResultsA total of 222,020 high-confidence RNA editing sites were identified, of which approximately 98% were A-to-I events, including 124,486 ESCC-specific edits predominantly enriched in introns, 3' untranslated regions, and non-coding RNAs, highlighting a pervasive post-transcriptional regulatory layer. RNA A-to-I editing was extensively remodeled and globally up-regulated in non-metastatic ESCC, whereas only minimal changes were observed during lymph node metastasis, indicating that RNA editing alterations predominantly occur during early tumorigenesis. CDK13 emerged as a recurrent ADAR1 target, with RNA editing inversely correlated with CDK13 expression. ADAR1-mediated CDK13 editing established a positive feedback loop associated with enhanced interferon-stimulated gene (ISG) signaling and poorer survival in non-metastatic ESCC. Mechanistically, partial attenuation of CDK13 induced chronic, tumor cell-intrinsic activation of the cGAS-STING-ISG pathway. Integrated multi-omics analyses further revealed that CDK13 regulates phosphorylation networks governing cytoskeleton organization, intracellular trafficking, RNA homeostasis, and immune signaling. ConclusionRNA A-to-I editing represents a dynamic regulatory mechanism driving early ESCC progression and remodeling tumor cell-intrinsic immune signaling. ADAR1-mediated editing of CDK13 provides a mechanistic link between RNA editing and cGAS-STING-ISG pathway activation, revealing potential therapeutic vulnerabilities and supporting its utility as an early prognostic biomarker in ESCC.

Matching journals

The top 12 journals account for 50% of the predicted probability mass.

1
Genome Medicine
154 papers in training set
Top 0.4%
10.2%
2
Molecular Cancer
14 papers in training set
Top 0.1%
8.5%
3
Gastroenterology
40 papers in training set
Top 0.4%
4.9%
4
Nature Communications
4913 papers in training set
Top 36%
4.2%
5
Molecular Therapy
71 papers in training set
Top 0.6%
4.0%
6
Cell Reports
1338 papers in training set
Top 14%
3.7%
7
Advanced Science
249 papers in training set
Top 5%
3.6%
8
Nucleic Acids Research
1128 papers in training set
Top 6%
3.6%
9
Cancer Research
116 papers in training set
Top 1%
2.6%
10
Oncogene
76 papers in training set
Top 0.9%
1.9%
11
Computational and Structural Biotechnology Journal
216 papers in training set
Top 3%
1.9%
12
NAR Cancer
36 papers in training set
Top 0.1%
1.8%
50% of probability mass above
13
Journal of Translational Medicine
46 papers in training set
Top 0.7%
1.8%
14
Cancer Research Communications
46 papers in training set
Top 0.4%
1.7%
15
iScience
1063 papers in training set
Top 14%
1.7%
16
Clinical and Translational Medicine
30 papers in training set
Top 0.4%
1.5%
17
Cell Reports Medicine
140 papers in training set
Top 4%
1.5%
18
npj Genomic Medicine
33 papers in training set
Top 0.4%
1.5%
19
Gut
36 papers in training set
Top 0.6%
1.3%
20
PLOS Computational Biology
1633 papers in training set
Top 18%
1.3%
21
Cancer Letters
32 papers in training set
Top 0.5%
1.1%
22
Scientific Reports
3102 papers in training set
Top 69%
1.0%
23
Genomics, Proteomics & Bioinformatics
171 papers in training set
Top 5%
0.9%
24
Computers in Biology and Medicine
120 papers in training set
Top 4%
0.8%
25
Journal of Experimental & Clinical Cancer Research
25 papers in training set
Top 0.3%
0.8%
26
npj Precision Oncology
48 papers in training set
Top 1%
0.8%
27
PLOS ONE
4510 papers in training set
Top 67%
0.8%
28
Molecular Cancer Research
42 papers in training set
Top 0.7%
0.8%
29
Molecular Oncology
50 papers in training set
Top 1%
0.7%
30
EBioMedicine
39 papers in training set
Top 1%
0.7%